William L Trepicchio

7643943, Jan 5, 2010

Mar 5, 2004

10/793032

Michael E. Burczynski - Collegeville PA, US
Joseph Boni - Wayne PA, US
Andrew J. Dorner - Lexington MA, US
Natalie C. Twine - Goofstown NH, US
Jennifer Stover - Topsfield MA, US
William L. Trepicchio - Andover MA, US
Virginia Fitzpatrick - Norristown PA, US
Fred Immermann - Suffern NY, US

Wyeth LLC - Madison NJ

G01N 33/48

702 19

Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells are modulatable by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for detecting or monitoring drug activities in vivo.

20020037538, Mar 28, 2002

May 9, 2001

09/852400

William Trepicchio - Andover MA, US
Judith Oestreicher - Portsmouth NH, US
Andrew Dorner - Lexington MA, US
James Krueger - New York NY, US

G01N033/567
C12Q001/68

435/007210, 435/006000

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating psoriasis. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of psoriasis.

20020039734, Apr 4, 2002

May 17, 2001

09/860655

Catherine Hanrahan - London, GB
Marc Feldmann - London, GB
William Trepicchio - Andover MA, US

C12Q001/68
G01N033/574

435/006000, 435/007230

The invention relates to compositions, kits and methods for identifying, detecting, and modulating the differentiation, growth, and/or maturation of Th1 or Th2 cells. The invention further relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating a Th1- or Th2-associated condition. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of a Th1 or Th2 cell or Th1- or Th2-associated condition.

20030154032, Aug 14, 2003

Dec 17, 2001

10/023451

Debra Pittman - Windham NH, US
Jeffrey Feldman - Arlington MA, US
Kathleen Shields - Harvard MA, US
William Trepicchio - Andover MA, US

G06F019/00
G01N033/48

702/020000

The invention provides methods and compositions for diagnostic assays for detecting R.A. and therapeutic methods and compositions for treating R.A. The invention also provides methods for designing, identifying, and optimizing therapeutics for R.A. Diagnostic compositions of the invention include compositions comprising detection agents for detecting one or more genes that have been shown to be up- or down-regulated in cells of R.A. relative to normal counterpart cells. Exemplary detection agents include nucleic acid probes, which can be in solution or attached to a solid surface, e.g., in the form of a microarray. The invention also provides computer-readable media comprising values of levels of expression of one or more genes that are up- or down-regulated in R.A.

20040110221, Jun 10, 2004

Nov 21, 2003

10/717597

Natalie Twine - Goffstown NH, US
Michael Burczynski - Swampscott MA, US
William Trepicchio - Andover MA, US
Andrew Dorner - Lexington MA, US
Jennifer Stover - Topsfield MA, US
Donna Slonim - North Andover MA, US

Wyeth - Madison NJ

C12Q001/68
G01N033/574

435/006000, 435/007230

Methods, systems and equipment for diagnosing renal cell carcinoma (RCC) and other solid tumors. This invention identifies numerous disease genes that are differentially expressed in the peripheral blood of patients having RCC or other solid tumors relative to disease-free humans. These disease genes can be used as surrogate markers for detecting the presence or absence of RCC or other solid tumors.

20040175743, Sep 9, 2004

Feb 11, 2004

10/775169

Michael Burczynski - Swampscott MA, US
Natalie Twine - Goffstown NH, US
Andrew Dorner - Lexington MA, US
William Trepicchio - Andover MA, US

C12Q001/68
G01N033/567

435/006000, 435/007210

Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells can be modulated by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for monitoring drug activities in vivo.

20050202451, Sep 15, 2005

Apr 29, 2004

10/834114

Michael Burczynski - Swampscott MA, US
Andrew Dorner - Lexington MA, US
Natalie Twine - Goffstown NH, US
William Trepicchio - Andover MA, US
Jennifer Stover - Topsfield MA, US

C12Q001/68

435006000

Methods, systems and equipment for diagnosing or monitoring the progression or treatment of AML or MDS. This invention identifies a plurality of AML or MDS disease genes which are differentially expressed in bone marrow cells of AML or MDS patients as compared to disease-free humans. These AML or MDS disease genes can be used as molecular markers for detecting the presence or absence of AML or MDS. These genes can also be used for the early identification of MDS patients who eventually progress to AML.

20050244849, Nov 3, 2005

Dec 16, 2004

11/014625

Debra Pittman - Windham NH, US
Jeffrey Feldman - Arlington MA, US
Kathleen Shields - Harvard MA, US
William Trepicchio - Andover MA, US

Genetics Institute, LLC - Cambridge MA

C12Q001/68
G01N033/53
G06F019/00
G01N033/48
G01N033/50

435006000, 702019000, 702020000, 435007100

The invention provides methods for identifying, designing, and optimizing therapeutics for R.A using as targets one or more genes (and/or their encoded gene products) that have been shown to be up- or down-regulated in cells of R.A. relative to normal counterpart cells. Methods and compositions for diagnostic assays for detecting R.A. are also provided.